Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 159.10M P/E - EPS this Y 38.30% Ern Qtrly Grth -
Income -64.66M Forward P/E -2.11 EPS next Y 31.40% 50D Avg Chg 11.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -18.00%
Dividend N/A Price/Book 1.93 EPS next 5Y - 52W High Chg -64.00%
Recommedations 2.40 Quick Ratio 10.35 Shares Outstanding 29.84M 52W Low Chg 68.00%
Insider Own 21.85% ROA -42.89% Shares Float 10.34M Beta -0.21
Inst Own 61.79% ROE -69.48% Shares Shorted/Prior 249.63K/386.84K Price 8.19
Gross Margin - Profit Margin - Avg. Volume 98,716 Target Price 10.33
Oper. Margin - Earnings Date - Volume 8,781 Change -0.12%
About AN2 Therapeutics, Inc.

AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, which is in a pivotal Phase 2/3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease. The company also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chagas disease that is in preclinical trials. It has a license agreement with Anacor Pharmaceuticals, Inc. to use, develop, manufacture, commercialize, or otherwise exploit certain compounds and products, including epetraborole, for the treatment, diagnosis, or prevention of all human diseases; and Brii Biosciences Limited to research, develop, manufacture, and commercialize certain compounds and products, including epetraborole, in China, Hong Kong, Taiwan, and Macau for the diagnosis, treatment, and prevention of human diseases. The company was incorporated in 2017 and is headquartered in Menlo Park, California.

AN2 Therapeutics, Inc. News
11/21/24 Immuneering Leads The Pack Of 3 US Penny Stocks To Monitor
11/14/24 AN2 Therapeutics to Participate at Upcoming Investor Conferences
11/13/24 AN2 Therapeutics Reports Third Quarter 2024 Financial Results, Provides Important EBO-301 Update and Highlights Progress Across Boron Chemistry Pipeline
10/17/24 AN2 Therapeutics Receives Continuation Grant to Discover Novel Boron Based Therapies for Tuberculosis (caused by Mycobacterium tuberculosis) and Malaria
03:00 PM AN2 Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
08/19/24 AN2 Therapeutics (ANTX) Plunges 66% in a Month: Here's Why
08/16/24 AN2 Therapeutics Adopts Limited Duration Stockholder Rights Plan
08/13/24 AN2 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business and Scientific Highlights
08/09/24 Top Midday Decliners
08/09/24 Lung Disease Focused AN2 Therapeutics' Lackluster Data Prompts To Stop Phase 3 Study Of Lung Infection Candidate, Halves Workforce
08/09/24 AN2 slashes staff by 50% after lead antibiotic flunks in Phase II/III trial
08/09/24 AN2 Therapeutics to Discontinue Clinical Study of Lung Disease Drug Candidate Epetraborole; Shares Plunge Pre-Bell
08/08/24 AN2 Therapeutics Provides Update on EBO-301 Phase 2/3 Study Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium Complex (MAC) Lung Disease
07/12/24 Here's Why We're Watching AN2 Therapeutics' (NASDAQ:ANTX) Cash Burn Situation
07/03/24 Intuit initiated, Charter downgraded: Wall Street's top analyst calls
05/21/24 Down -5.51% in 4 Weeks, Here's Why AN2 Therapeutics (ANTX) Looks Ripe for a Turnaround
05/14/24 AN2 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business and Scientific Highlights
03:10 PM AN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific Highlights
02/22/24 13 Best Falling Stocks To Buy Right Now
02/12/24 UPDATE 1-AN2 Therapeutics to pause lung disease study enrollment
ANTX Chatroom

User Image mhaven2020 Posted - 7 hours ago

$RMSL I'll let you know when I find some good ones. $RCAT $QBTS $ANTX. Focusing on one week holds or there about.

User Image lpInvestor Posted - 4 days ago

$ANTX

User Image NVDAMillionaire Posted - 1 week ago

$ANTX AN2 Therapeutics (ANTX): Overcoming Challenges, Advancing Innovative Boron-Based Therapeutics https://beyondspx.com/article/an2-therapeutics-antx-overcoming-challenges-advancing-innovative-boron-based-therapeutics

User Image ka1954 Posted - 1 week ago

$ANTX back to $1 soon. fucked up stock !!!

User Image lealbinagor98 Posted - 1 week ago

$ANTX good time to enter and wait for the results of the first quarter, if it is positive this is triggered, you have to be patient $LCTX $TNXP $SCLX

User Image ka1954 Posted - 1 week ago

$ANTX slow as a motherfucker. why can't this fucker just go already ? down 94% for the year, atleast could have reduced this percentage

User Image frontiere Posted - 2 weeks ago

$BRNS Barinthus ref=$0.8611 on very low volumes — if the IR team could whisper this advice to the Mgmt / Board, please: have CEO Mr Enright, and/or COO Mr Griffiths, and any other Board member and Executive team member BUY THE STOCK IN THE OPEN MARKET. SHOW your confidence in the company, remind the market how cheap BRNS is, and drum up interest and volumes! This worked great for $ANTX AN2, $VTYX Ventyx and others recently — in fact hard to remember when it didn’t!

User Image ka1954 Posted - 2 weeks ago

$ANTX why the fuck this stock moves only when we have insider buying? can we see 2.50 already so i can sell this and move on

User Image AZOZ Posted - 2 weeks ago

$ANTX insider's activitiy!

User Image Gorilla_Trading Posted - 2 weeks ago

$ANTX

User Image Gorilla_Trading Posted - 2 weeks ago

$ANTX insider buying

User Image db1113 Posted - 2 weeks ago

$ANTX 🚨 INSIDER BUYING ALERT $ANTX Director Robin Readnour just scooped up 60,000 shares worth $86.7K in AN2 Therapeutics! Multiple buys between Dec 6-10 showing serious conviction! Stock down 95% YTD - potential bottom fishing?

User Image JacoI3 Posted - 3 weeks ago

$ANTX Too illiquid for me. Out

User Image Gwen_Gainax Posted - 3 weeks ago

$ANTX disregard. I'm back in and holding will DCA

User Image Gwen_Gainax Posted - 3 weeks ago

$ANTX breaking down on the daily. Will reposition on breakout

User Image Gwen_Gainax Posted - 3 weeks ago

$ANTX once it clears 1.66-1.69 it's going to take off like a rocket. Grabbing a small starter and stop under the where momentum turns

User Image KUMU Posted - 3 weeks ago

$ANTX went short here into dilution

User Image showtime1 Posted - 3 weeks ago

$ANTX

User Image PiercingVenom Posted - 11/30/24

$BREA Massive gap incoming on Monday. BREA make sure not to miss out. #2 Trending ✅️ $DSY looks good $ANTX I have some $SDOT Low float

User Image Bkktmasterhold55 Posted - 11/30/24

$ANTX looking good

User Image hermitkatt Posted - 11/29/24

$ANTX nice move

User Image bull130 Posted - 11/29/24

$ANTX Can we see 3 by the end of the year?

User Image ItTakesItAll Posted - 11/29/24

$ANTX 30%+ little better huh?

User Image showtime1 Posted - 11/29/24

$ANTX Holding from .99 entry now insiders loading🤑

User Image eyeownu Posted - 11/29/24

$ANTX wonder whats up

User Image ka1954 Posted - 11/29/24

$ANTX this is freaking slow as hell. i see stocks going 200%+ everyday and we can't even manage 20%

User Image JacoI3 Posted - 11/29/24

$ANTX Bought the top. Hang on 🫣

User Image AZOZ Posted - 11/29/24

$RPID $ANTX Insider's loading!

User Image showtime1 Posted - 1 month ago

$ANTX Director adding on the way up..

User Image showtime1 Posted - 1 month ago

$ANTX Small insider buy..

Analyst Ratings
JMP Securities Market Outperform Aug 9, 24
Leerink Partners Outperform Jul 3, 24
Evercore ISI Group In-Line May 16, 24
JMP Securities Market Outperform Apr 2, 24
Oppenheimer Perform Apr 1, 24
Leerink Partners Market Perform Feb 13, 24
Evercore ISI Group In-Line Feb 12, 24
Oppenheimer Perform Feb 12, 24
JMP Securities Market Perform Feb 12, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Zakrzewski Joseph S Director Director Jan 18 Sell 19.1141 100,000 1,911,410 405,880 01/19/24
Aziz Kabeer Director Director Jan 16 Sell 19.65 100,000 1,965,000 377,542 01/18/24
Adjuvant Global Health Technol... Director Director Jan 16 Sell 19.65 100,000 1,965,000 377,542 01/18/24
Readnour Robin Shane Director Director Jan 12 Sell 21.92 1,425 31,236 485,073 01/17/24
Readnour Robin Shane Director Director Jan 10 Sell 21.93 3,669 80,461 485,792 01/12/24
Krause Kevin Michael Chief Strategy Offic.. Chief Strategy Officer Jan 09 Sell 20.14 7,417 149,378 1,914 01/11/24
Krause Kevin Michael Chief Strategy Offic.. Chief Strategy Officer Jan 09 Option 3.51 7,417 26,034 9,331 01/11/24
Krause Kevin Michael Chief Strategy Offic.. Chief Strategy Officer Jan 02 Sell 20.12 2,583 51,970 1,914 01/04/24
Krause Kevin Michael Chief Strategy Offic.. Chief Strategy Officer Jan 02 Option 0.42 2,583 1,085 4,497 01/04/24
Easom Eric Chief Executive Offi.. Chief Executive Officer Jan 02 Sell 20.0945 2,777 55,802 2,130 01/04/24
Adjuvant Global Health Technol... Director Director Nov 14 Sell 16.15 1,810 29,231 393,449 11/16/23
Aziz Kabeer Director Director Nov 14 Sell 16.15 1,810 29,231 393,449 11/16/23
Aziz Kabeer Director Director Sep 29 Sell 16.18 104,773 1,695,227 393,737 10/03/23
Adjuvant Global Health Technol... Director Director Sep 29 Sell 16.18 104,773 1,695,227 393,737 10/03/23
Adjuvant Global Health Technol... Director Director Sep 27 Sell 16.09 9,357 150,554 410,403 09/29/23
Aziz Kabeer Director Director Sep 27 Sell 16.09 9,357 150,554 410,403 09/29/23
Aziz Kabeer Director Director Aug 23 Sell 16 400 6,400 411,893 09/15/23
Adjuvant Global Health Technol... Director Director Aug 23 Sell 16 400 6,400 411,893 09/15/23
RA CAPITAL MANAGEMENT, L.P. 10% Owner 10% Owner Aug 18 Buy 9.00 1,777,778 16,000,002 5,135,683 08/22/23
Easom Eric Chief Executive Offi.. Chief Executive Officer May 15 Buy 5.377 10,000 53,770 1,015,766 05/15/23
Easom Eric Chief Executive Offi.. Chief Executive Officer Nov 10 Sell 15.18 4,436 67,338 4,907 11/14/22
Easom Eric Chief Executive Offi.. Chief Executive Officer Nov 08 Sell 15.8 17,166 271,223 4,907 11/09/22
Easom Eric Chief Executive Offi.. Chief Executive Officer Nov 03 Sell 16.02 35,196 563,840 4,907 11/07/22
Easom Eric Chief Executive Offi.. Chief Executive Officer Oct 31 Sell 15.23 4,232 64,453 4,907 11/02/22
Easom Eric Chief Executive Offi.. Chief Executive Officer Oct 27 Sell 15.22 2,607 39,679 4,907 10/28/22
Easom Eric Chief Executive Offi.. Chief Executive Officer Oct 24 Sell 15.79 9,350 147,636 4,907 10/26/22
Easom Eric Chief Executive Offi.. Chief Executive Officer Oct 20 Sell 16.7 21,244 354,775 4,907 10/24/22
RA CAPITAL MANAGEMENT, L.P. 10% Owner 10% Owner Jul 26 Buy 7.81 23,219 181,340 3,771,608 07/28/22
Adjuvant Global Health Technol... 10% Owner 10% Owner Mar 29 Buy 15 166,666 2,499,990 2,210,735 06/24/22
Readnour Robin Shane Director Director Mar 29 Buy 15 153,334 2,300,010 487,592 03/31/22
Aziz Kabeer Director Director Mar 29 Buy 15 166,666 2,499,990 2,210,735 03/31/22